These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9463192)

  • 1. [The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis].
    Sampaio RN; de Paula CD; Sampaio JH; Furtado Rde S; Leal PP; Rosa TT; Rodrigues ME; Veiga JP
    Rev Soc Bras Med Trop; 1997; 30(6):457-63. PubMed ID: 9463192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds].
    Veiga JP; Rosa TT; Kimachi T; Wolff ER; Sampaio RN; Gagliardi AR; Junqueira Júnior LF; Costa JM; Marsden PD
    Rev Inst Med Trop Sao Paulo; 1985; 27(6):298-302. PubMed ID: 3014634
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials.
    Veiga JP; Wolff ER; Sampaio RN; Marsden PD
    Lancet; 1983 Sep; 2(8349):569. PubMed ID: 6136717
    [No Abstract]   [Full Text] [Related]  

  • 4. Retention of antimony in hair during leishmaniasis treatment.
    Dorea JG; Merchan-Hamann E; Ryan DE; Holzbecher J
    Clin Chim Acta; 1989 Feb; 179(3):341-5. PubMed ID: 2714007
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
    Soto J; Hernandez N; Mejia H; Grogl M; Berman J
    Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of urticaria during pentavalent antimony use in a patient with mucous leishmaniasis].
    Oliveira MR; Marsden PD
    Rev Soc Bras Med Trop; 1995; 28(3):287. PubMed ID: 7480927
    [No Abstract]   [Full Text] [Related]  

  • 7. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate.
    Friedrich K; Vieira FA; Porrozzi R; Marchevsky RS; Miekeley N; Grimaldi G; Paumgartten FJ
    J Toxicol Environ Health A; 2012; 75(2):63-75. PubMed ID: 22129235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimony excretion in a patient with renal impairment during meglumine antimoniate therapy.
    Hantson P; Luyasu S; Haufroid V; Lambert M
    Pharmacotherapy; 2000 Sep; 20(9):1141-3. PubMed ID: 10999510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis.
    Berhe N; Abraham Y; Hailu A; Ali A; Mengistu G; Tsige K; Abebe Y
    East Afr Med J; 2001 Nov; 78(11):608-10. PubMed ID: 12219968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
    Castro C; Sampaio RN; Marsden PD
    Trans R Soc Trop Med Hyg; 1990; 84(3):362. PubMed ID: 2260169
    [No Abstract]   [Full Text] [Related]  

  • 11. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).
    Oliveira-Neto MP; Schubach A; Mattos M; Goncalves-Costa SC; Pirmez C
    Am J Trop Med Hyg; 1997 Dec; 57(6):651-5. PubMed ID: 9430521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A fatal case of mucocutaneous leishmaniasis after pentavalent antimonial use].
    Oliveira MC; Amorim RF; Freitas Rde A; Costa Ade L
    Rev Soc Bras Med Trop; 2005; 38(3):258-60. PubMed ID: 15895180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis.
    Gasser RA; Magill AJ; Oster CN; Franke ED; Grögl M; Berman JD
    Clin Infect Dis; 1994 Jan; 18(1):83-90. PubMed ID: 7519887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
    Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
    Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug hypersensitivity syndrome induced by meglumine antimoniate.
    Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
    Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis.
    Ventin F; Cincurá C; Machado PRL
    Expert Rev Anti Infect Ther; 2018 Mar; 16(3):219-225. PubMed ID: 29411659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable.
    de Oliveira-Neto MP; Mattos Mda S
    Rev Soc Bras Med Trop; 2006; 39(4):323-6. PubMed ID: 17119744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis.
    Llanos-Cuentas A; Echevarria J; Seas C; Chang E; Cruz M; Alvarez E; Rosales E; Campos P; Bryceson A
    Am J Trop Med Hyg; 2007 Jun; 76(6):1128-31. PubMed ID: 17556623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of mucocutaneous leishmaniasis treated with success with a low dose of pentavalent antimonial].
    Amato VS; de Oliveira LS; Silva AC; Machado FR; Amato JG; Nicodemo AC; Amato Neto V
    Rev Soc Bras Med Trop; 1998; 31(2):221-4. PubMed ID: 9608241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful therapeutic response of resistant cases of mucocutaneous leishmaniasis to a very low dose of antimony.
    de Oliveira-Neto MP; Mattos Mda S
    Rev Soc Bras Med Trop; 2006; 39(4):376-8. PubMed ID: 17119754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.